In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: A pilot study
Maschauer S, Ruckdeschel T, Tripal P, Haubner R, Einsiedel J, Hübner H, Gmeiner P, Kuwert T, Prante O (2014)
Publication Language: English
Publication Type: Journal article, Original article
Publication year: 2014
Journal
Original Authors: Maschauer S., Ruckdeschel T., Tripal P., Haubner R., Einsiedel J., Hubner H., Gmeiner P., Kuwert T., Prante O.
Publisher: MDPI
Book Volume: 7
Pages Range: 464-481
Journal Issue: 4
DOI: 10.3390/ph7040464
Abstract
The neurotensin receptor (NTS1) has emerged as an interesting target for molecular imaging and radiotherapy of NTS-positive tumors due to the overexpression in a range of tumors. The aim of this study was to develop a Lu-labeled NTS1 radioligand, its application for radiotherapy in a preclinical model and the imaging of therapy success by small-animal positron emission tomography (μPET) using [Ga]DOTA-RGD as a specific tracer for imaging angiogenesis. The Lu-labeled peptide was subjected to studies on HT29-tumor-bearing nude mice in vivo, defining four groups of animals (single dose, two fractionated doses, four fractionated doses and sham-treated animals). Body weight and tumor diameters were determined three times per week. Up to day 28 after treatment, μPET studies were performed with [Ga]DOTA-RGD. At days 7-10 after treatment with four fractionated doses of 11-14 MBq (each at days 0, 3, 6 and 10), the tumor growth was slightly decreased in comparison with untreated animals. Using a single high dose of 51 MBq, a significantly decreased tumor diameter of about 50% was observed with the beginning of treatment. Our preliminary PET imaging data suggested decreased tumor uptake values of [Ga]DOTA-RGD in treated animals compared to controls at day 7 after treatment. This pilot study suggests that early PET imaging with [Ga]DOTA-RGD in radiotherapy studies to monitor integrin expression could be a promising tool to predict therapy success in vivo. Further successive PET experiments are needed to confirm the significance and predictive value of RGD-PET for NTS-mediated radiotherapy. © 2014 by the authors; licensee MDPI, Basel, Switzerland.
Authors with CRIS profile
Simone Maschauer
Professur für Molekulare Bildgebung und Radiochemie
Philipp Tripal
Optical Imaging Center Erlangen (OICE)
Jürgen Einsiedel
Lehrstuhl für Pharmazeutische Chemie
Harald Hübner
Lehrstuhl für Pharmazeutische Chemie
Peter Gmeiner
Lehrstuhl für Pharmazeutische Chemie
Torsten Kuwert
Lehrstuhl für Klinische Nuklearmedizin
Olaf Prante
Professur für Molekulare Bildgebung und Radiochemie
Additional Organisation(s)
Involved external institutions
Austria (AT)How to cite
APA:
Maschauer, S., Ruckdeschel, T., Tripal, P., Haubner, R., Einsiedel, J., Hübner, H.,... Prante, O. (2014). In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: A pilot study. Pharmaceuticals, 7(4), 464-481. https://dx.doi.org/10.3390/ph7040464
MLA:
Maschauer, Simone, et al. "In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: A pilot study." Pharmaceuticals 7.4 (2014): 464-481.
BibTeX: Download